Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Synaffix and Elevation Oncology have entered into a licensing agreement for ADC (antibody-drug conjugate) technology development. The deal grants Elevation Oncology access to Synaffix's clinical-stage ADC platform, including GlycoConnect®, HydraSpace®, and toxSYN® technologies, to develop a novel HER3 ADC candidate named EO-1022.
Under the agreement terms, Synaffix could receive up to $368 million in upfront and milestone payments, plus tiered royalties on net sales. Synaffix will manufacture technology components while Elevation Oncology handles research, development, manufacturing, and commercialization of the ADC. The partnership aims to develop treatments for patients with HER3-expressing solid tumors.
Synaffix ed Elevation Oncology hanno stipulato un accordo di licenza per lo sviluppo della tecnologia ADC (conjugato anticorpo-farmaco). L'accordo consente a Elevation Oncology di accedere alla piattaforma ADC in fase clinica di Synaffix, comprese le tecnologie GlycoConnect®, HydraSpace® e toxSYN®, per sviluppare un nuovo candidato ADC HER3 chiamato EO-1022.
Secondo i termini dell'accordo, Synaffix potrebbe ricevere fino a $368 milioni in pagamenti anticipati e per traguardi, oltre a royalties progressive sulle vendite nette. Synaffix si occuperà della produzione dei componenti tecnologici mentre Elevation Oncology gestirà la ricerca, lo sviluppo, la produzione e la commercializzazione dell'ADC. La partnership mira a sviluppare trattamenti per i pazienti affetti da tumori solidi che esprimono HER3.
Synaffix y Elevation Oncology han firmado un acuerdo de licencia para el desarrollo de tecnología ADC (conjugado anticuerpo-fármaco). El acuerdo otorga a Elevation Oncology acceso a la plataforma ADC en fase clínica de Synaffix, incluyendo las tecnologías GlycoConnect®, HydraSpace® y toxSYN®, para desarrollar un nuevo candidato ADC HER3 denominado EO-1022.
Según los términos del acuerdo, Synaffix podría recibir hasta $368 millones en pagos iniciales y por hitos, además de royalties escalonados sobre las ventas netas. Synaffix fabricará los componentes tecnológicos, mientras que Elevation Oncology se encargará de la investigación, el desarrollo, la fabricación y la comercialización del ADC. La asociación tiene como objetivo desarrollar tratamientos para pacientes con tumores sólidos que expresan HER3.
Synaffix와 Elevation Oncology가 항체-약물 접합체(ADC) 기술 개발을 위한 라이센스 계약을 체결했습니다. 이 계약은 Elevation Oncology가 Synaffix의 임상 단계 ADC 플랫폼에 접근할 수 있도록 하며, GlycoConnect®, HydraSpace®, toxSYN® 기술을 포함하여 EO-1022라는 새로운 HER3 ADC 후보를 개발하는 것입니다.
계약 조건에 따르면, Synaffix는 최대 $368백만의 선급 및 이정표 지급을 받을 수 있으며, 순매출에 대한 단계별 로열티를 추가로 받을 수 있습니다. Synaffix는 기술 구성 요소를 제조하고, Elevation Oncology는 ADC의 연구, 개발, 제조 및 상용화 작업을 담당합니다. 이 파트너십은 HER3을 발현하는 고형 종양 환자를 위한 치료법 개발을 목표로 하고 있습니다.
Synaffix et Elevation Oncology ont conclu un accord de licence pour le développement de la technologie ADC (conjugat anticorps-médicament). Cet accord donne à Elevation Oncology accès à la plateforme ADC en phase clinique de Synaffix, y compris les technologies GlycoConnect®, HydraSpace® et toxSYN®, pour développer un nouveau candidat ADC HER3 nommé EO-1022.
Selon les termes de l'accord, Synaffix pourrait recevoir jusqu'à 368 millions de dollars en paiements initiaux et de jalons, ainsi que des redevances progressives sur les ventes nettes. Synaffix fabriquera les composants technologiques tandis qu'Elevation Oncology s'occupera de la recherche, du développement, de la fabrication et de la commercialisation de l'ADC. Le partenariat vise à développer des traitements pour les patients atteints de tumeurs solides exprimant HER3.
Synaffix und Elevation Oncology haben eine Lizenzvereinbarung zur Entwicklung von ADC (Antikörper-Wirkstoff-Konjugat) Technologie abgeschlossen. Der Deal gibt Elevation Oncology Zugang zur klinischen ADC-Plattform von Synaffix, einschließlich GlycoConnect®, HydraSpace® und toxSYN® Technologien, um einen neuartigen HER3 ADC Kandidaten namens EO-1022 zu entwickeln.
Nach den Bedingungen der Vereinbarung könnte Synaffix bis zu $368 Millionen an Vorauszahlungen und Meilensteinzahlungen erhalten, sowie gestaffelte Lizenzgebühren auf Nettoumsätze. Synaffix wird die technologischen Komponenten herstellen, während Elevation Oncology die Forschung, Entwicklung, Produktion und Markteinführung des ADC übernimmt. Die Partnerschaft zielt darauf ab, Behandlungen für Patienten mit HER3-expressierenden soliden Tumoren zu entwickeln.
- Potential revenue of up to $368 million plus royalties from milestone payments
- Partnership expands commercial applications of Synaffix's ADC technology platform
- Clear division of responsibilities: Synaffix handles technology components, Elevation manages development
- None.
- Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™
- Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologies
Synaffix gives Elevation Oncology global access to its clinical stage, site-specific ADC technology platform, including GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, as well as the toxSYN® linker-payload, SYNstatin E™, which enables the transformation of Elevation Oncology's antibody into a differentiated ADC with best-in-class potential.
Under the terms of the agreement, Synaffix is eligible to receive up to
Peter van de Sande, Head of Synaffix, said: "As a dedicated partner in the ADC space, Synaffix is excited to collaborate with Elevation Oncology to push the boundary of ADC innovation. With our state-of-the-art ADC technology platform and established supply chain, Elevation is well-positioned to accelerate the development of its differentiated HER3 ADC."
David Dornan, Chief Scientific Officer at Elevation Oncology, commented: "Our partnership with Synaffix enables us to build a HER3 ADC candidate with best-in-class potential, which leverages Synaffix's state-of-the-art site-specific conjugation and differentiated linker-payload for a potentially improved safety and efficacy profile. We look forward to advancing our pipeline as we work toward transforming the care and treatment of patients living with solid tumors that express HER3."
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.
The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen (acquired by Lepu Biopharma), Innovent Biologics, Kyowa Kirin, Genmab, Macrogenics, Amgen, Hummingbird Biosciences, Chong Kun Dang Pharma, ABL Bio, SOTIO Biotech, Kivu Bioscience, BigHat Biosciences, Illuminaand Elevation Oncology.
Synaffix was fully acquired by Lonza in June 2023.
About The Synaffix ADC Platform Technology
Synaffix's proprietary ADC technology platform consists of GlycoConnect®, GlycoConnect™ High DAR Technology, HydraSpace®, and toxSYN®. These technologies are aimed at enabling best-in-class ADCs from any antibody, with significantly enhanced efficacy and tolerability.
GlycoConnect® clinical-stage conjugation technology exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats. The extension of GlycoConnect® with High DAR Technology enables ADCs with high drug loading (6, 8 and above), while retaining high drug substance homogeneity and therapeutic index. HydraSpace® clinical-stage compact and highly polar spacer technology is designed to further enhance therapeutic index, particularly with hydrophobic payloads. toxSYN® linker-payload platform spans key, validated MOAs for ADC product development. This includes potent topoisomerase 1 inhibitor (SYNtecan E™), DNA damaging agents (SYNeamicin D™ and SYNeamicin G™), ⍺-Microtubule (SYNtansine™) and β-Microtubule (SYNstatin E™ and SYNstatin F™) inhibitors as well as several unlaunched proprietary linker-payloads that were generated through the ongoing innovative efforts of the Synaffix R&D team.
The newest proprietary linker-payload, "SYN-PNU™" is part of the established and expanding toxSYN® linker-payload portfolio. SYN-PNU™ represents (based on pre-clinical models) a significantly potency-attenuated and better tolerated version of PNU-159,682, to enable enhanced administered dose levels and competitive therapeutic properties versus ADCs prepared using the original molecule. The reference compound (PNU-159,682) is a metabolite of the anthracycline Nemorubicin and represents a highly potent DNA topoisomerase II inhibitor.
The combination of these three technologies provides developers with a "one stop" and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.
About Lonza
Lonza is one of the world's largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.
Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of
Follow @Lonza on LinkedIn
Follow @LonzaGroup on X
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. We are also advancing EO-1022, a HER3-targeting ADC for the treatment of patients living with solid tumors that express HER3, through preclinical development. For more information, visit www.ElevationOncology.com.
View original content:https://www.prnewswire.com/news-releases/elevation-oncology-licenses-adc-technology-from-synaffix-to-drive-pipeline-expansion-302329289.html
SOURCE Synaffix B.V.
FAQ
What is the maximum value of the licensing deal between Synaffix and Elevation Oncology?
What technologies are included in the Synaffix-Elevation Oncology licensing agreement?
What is the target of Elevation Oncology's new ADC candidate EO-1022?
How are responsibilities divided in the Synaffix-Elevation Oncology partnership?
